We recently demonstrated successful in vitro and in vivo re-sensitization of multiple cisplatin-resistant ovarian cancer cell lines using a novel small-molecule DNMT inhibitor guadecitabine (SGI-110) [275]. Here, DNMT1 is linked to ovarian cancer.